An immunological and transcriptomics approach on differential modulation of NK cells in multiple sclerosis patients under interferon-beta 1 and fingolimod therapy
JOURNAL OF NEUROIMMUNOLOGY, vol.347, 2020 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 347
- Publication Date: 2020
- Doi Number: 10.1016/j.jneuroim.2020.577353
- Journal Name: JOURNAL OF NEUROIMMUNOLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Psycinfo, Veterinary Science Database
- Keywords: Fingolimod, Interferon, Next-generation sequencing, NKp46, Immunomodulation, Multiple sclerosis, NK cells, NATURAL-KILLER-CELLS, EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS, PERIPHERAL-BLOOD, FTY720, SUBSETS, MECHANISMS
- Hacettepe University Affiliated: Yes
Abstract
This study aims to compare NK cells obtained from multiple sclerosis (MS) patients receiving interferon-beta 1 and fingolimod therapies. Fingolimod reduced the CD56(bright) NK cell subset. The remaining CD56(dim) NK cells displayed NKG2D, NKp46, CD107a, and IFN-gamma levels similar to those from the patients under interferon-beta 1 therapy. Alternatively, comparative transcriptomics and pathway analyses revealed significant distinctions between two therapy modalities. Molecular signature of the CD56(dim) NK cells from fingolimod-treated MS patients was closely associated to those from healthy subjects. The basic assets of NK cells were modestly influenced by interferon-beta 1 and fingolimod, however transcriptomics showed profound alterations in NK responses.